secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001140361-23-016314
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals appoints Mark White as CMO; Schwartz shifts to Chief Gene Therapy Officer
--------------------------------------------------------------------------------

- Mark White appointed Chief Medical Officer effective April 4, 2023; previously Global Franchise Head for Fasenra at AstraZeneca.
- Jonathan Schwartz transitions to newly created Chief Gene Therapy Officer, focusing on gene therapy strategy and external opportunities.
- White receives $450k base salary, 45% target bonus, and ~$2M equity grant (1/3 options, 2/3 RSUs) with standard vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/0001140361-23-016314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036123016314/brhc10051024_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-016314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer